Paraneoplastic Anti-3-hydroxy-3-methylglutary-coenzyme A Reductase Antibody-positive Immune-mediated Necrotizing Myopathy in a Patient with Uterine Cancer

We report the case of a 69-year-old woman with proximal limb muscle weakness, who received post-operative chemotherapy for uterine cancer. Her serum creatinine kinase level was high (10,779 mg/dL) and a muscle biopsy from her left biceps revealed various sizes of muscle fibers accompanied by necrotic and regenerating fibers. She was positive for anti-3 hydroxy-3-methylglutary-coenzyme A reductase (anti-HMGCR) antibodies, but negative for anti-signal recognition particle (anti-SRP) antibodies. She was diagnosed with immune-mediated necrotizing myopathy (IMNM) and treated with prednisolone. Our findings indicate that not only drug-induced myopathy but also paraneoplastic myopathy can be involved in the pathogenesis of IMNM.

[1]  I. Nishino,et al.  Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  Chunxiao Zhou,et al.  The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer , 2015, Oncotarget.

[3]  A. Pestronk,et al.  Myopathy with anti-HMGCR antibodies , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[4]  K. Jirström,et al.  Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients , 2015, BMC Clinical Pathology.

[5]  F. Mastaglia,et al.  Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. , 2015, Biochimica et biophysica acta.

[6]  L. Servais,et al.  Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies , 2014, Medicine.

[7]  A. Mammen,et al.  Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. , 2012, Arthritis and rheumatism.

[8]  A. Mammen,et al.  Rarity of anti–3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase antibodies in statin users, including those with self‐limited musculoskeletal side effects , 2012, Arthritis care & research.

[9]  A. Mammen,et al.  Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. , 2011, Arthritis and rheumatism.

[10]  F. Mastaglia,et al.  Progressive myopathy with up-regulation of MHC-I associated with statin therapy , 2007, Neuromuscular Disorders.

[11]  R. Hughes,et al.  119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands , 2004, Neuromuscular Disorders.

[12]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[13]  Nagaraju,et al.  A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli , 1998, Clinical and experimental immunology.